Jan Oldenburg

7.5k total citations · 3 hit papers
76 papers, 2.4k citations indexed

About

Jan Oldenburg is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Jan Oldenburg has authored 76 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Surgery, 38 papers in Pulmonary and Respiratory Medicine and 31 papers in Oncology. Recurrent topics in Jan Oldenburg's work include Testicular diseases and treatments (30 papers), Prostate Cancer Treatment and Research (20 papers) and PARP inhibition in cancer therapy (14 papers). Jan Oldenburg is often cited by papers focused on Testicular diseases and treatments (30 papers), Prostate Cancer Treatment and Research (20 papers) and PARP inhibition in cancer therapy (14 papers). Jan Oldenburg collaborates with scholars based in Norway, Germany and United States. Jan Oldenburg's co-authors include Sophie D. Fosså, Alv A. Dahl, Hege Sagstuen Haugnes, Carsten Bokemeyer, Peter Albers, Nicola Nicolai, Gabriella Cohn‐Cedermark, Ferrán Algaba, Karim Fizazi and A. Horwich and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Jan Oldenburg

74 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Guidelines on Testicular Cancer: 2015 Update

2015 454 citations Peter Albers, Carsten Bokemeyer et al. European Urology profile →
European Association of Urology Guidelines on Testicular Cancer: 2023 Update

2023 99 citations Daniel M. Berney, Stefanie Fischer et al. European Urology profile →
Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up

2022 99 citations Jan Oldenburg, Daniel M. Berney et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jan Oldenburg Norway	23	1.7k	713	595	531	518	76	2.4k
D.P. Dearnaley United Kingdom	25	1.3k 0.8×	743 1.0×	454 0.8×	377 0.7×	378 0.7×	56	2.2k
Carl W. Langberg Norway	23	875 0.5×	555 0.8×	407 0.7×	257 0.5×	244 0.5×	45	2.0k
Marianne Brydøy Norway	18	735 0.4×	283 0.4×	275 0.5×	120 0.2×	461 0.9×	38	1.3k
M.A. Kuczyk Germany	22	696 0.4×	488 0.7×	530 0.9×	100 0.2×	161 0.3×	120	1.5k
Willemina M. Molenaar Netherlands	30	519 0.3×	1.2k 1.7×	594 1.0×	460 0.9×	69 0.1×	90	2.4k
Sandra K. Althouse United States	20	516 0.3×	500 0.7×	352 0.6×	61 0.1×	117 0.2×	105	1.5k
Nadège Corradini France	27	305 0.2×	994 1.4×	552 0.9×	431 0.8×	49 0.1×	134	2.3k
Andrés Matoso United States	28	919 0.5×	1.1k 1.5×	1.0k 1.7×	308 0.6×	132 0.3×	143	2.7k
Graziella Cefalo Italy	27	261 0.1×	747 1.0×	434 0.7×	226 0.4×	62 0.1×	76	1.9k
Gabriele Amann Austria	28	837 0.5×	1.3k 1.8×	973 1.6×	530 1.0×	39 0.1×	125	3.5k

Countries citing papers authored by Jan Oldenburg

Since Specialization

Citations

This map shows the geographic impact of Jan Oldenburg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Oldenburg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Oldenburg more than expected).

Fields of papers citing papers by Jan Oldenburg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Oldenburg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Oldenburg. The network helps show where Jan Oldenburg may publish in the future.

Co-authorship network of co-authors of Jan Oldenburg

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Oldenburg. A scholar is included among the top collaborators of Jan Oldenburg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Oldenburg. Jan Oldenburg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jonasson, Christian, Christian Beisland, Tom Børge Johannesen, et al.. (2025). Overall Survival of Patients with Metastatic Renal Cell Carcinoma Following the Introduction of Targeted and Immunotherapies: A Norwegian Retrospective, Real-World Registry Data Study (RECON3). Cancer Management and Research. Volume 17. 103–112. 1 indexed citations

Galsky, Matthew D., Michiel S. van der Heijden, Thomas Powles, et al.. (2025). Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial. European Urology. 88(4). 325–330.

Agarwal, Neeraj, Arun Azad, Joan Carles, et al.. (2025). Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial.. Journal of Clinical Oncology. 43(5_suppl). 11 indexed citations

Galsky, Matt D., Guru Sonpavde, Thomas Powles, et al.. (2024). Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial.. Journal of Clinical Oncology. 42(16_suppl). 4509–4509. 11 indexed citations

Azad, Arun, André P. Fay, Cezary Szczylik, et al.. (2024). 1637P Efficacy of talazoparib and enzalutamide in mCRPC patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel: Post hoc analysis from both cohorts in TALAPRO-2 study. Annals of Oncology. 35. S987–S988. 1 indexed citations

Heijden, Michiel S. van der, Guru Sonpavde, Thomas Powles, et al.. (2023). LBA7 Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: Results from the phase III CheckMate 901 trial. Annals of Oncology. 34. S1341–S1341. 9 indexed citations

Albertsen, Peter C., et al.. (2023). Opportunistic prostate‐specific antigen testing in Norwegian men: a public health challenge. British Journal of Urology. 133(1). 104–111. 4 indexed citations

Oldenburg, Jan, Daniel M. Berney, Carsten Bokemeyer, et al.. (2022). Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. 33(4). 362–375. 99 indexed citations breakdown →

Crippa, Alessio, Bram De Laere, Andrea Discacciati, et al.. (2020). The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer. Trials. 21(1). 579–579. 19 indexed citations

10.

Eisen, Tim, Bernard Escudier, Stefanie Fischer, et al.. (2020). Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. ESMO Open. 5(Suppl 3). e000852–e000852. 19 indexed citations

11.

Türzer, Martin, et al.. (2019). Early experiences with PD-1 inhibitor treatment of platinum resistant epithelial ovarian cancer. Journal of Gynecologic Oncology. 30(4). e56–e56. 17 indexed citations

12.

Beisland, Christian, T.B. Johannesen, Olbjørn Klepp, et al.. (2017). Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study. OncoTargets and Therapy. Volume 10. 371–385. 27 indexed citations

13.

Tandstad, Torgrim, O. Ståhl, O. Dahl, et al.. (2016). Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Annals of Oncology. 27(7). 1299–1304. 67 indexed citations

14.

Gerwing, Mirjam, Christine Jacobsen, Sergey A. Dyshlovoy, et al.. (2016). Cabazitaxel overcomes cisplatin resistance in germ cell tumour cells. Journal of Cancer Research and Clinical Oncology. 142(9). 1979–1994. 12 indexed citations

15.

Bremnes, Roy M., Per Ole M. Gundersen, Mette Sprauten, et al.. (2016). Associations between long-term serum platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in testicular cancer survivors. Urologic Oncology Seminars and Original Investigations. 34(11). 487.e13–487.e20. 16 indexed citations

16.

Oldenburg, Jan, Jorge Aparicio, J. Beyer, et al.. (2014). Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer. Annals of Oncology. 26(5). 833–838. 45 indexed citations

17.

Tandstad, Torgrim, Arne Solberg, Ulf Håkansson, et al.. (2014). Bilateral testicular germ cell tumors in patients treated for clinical stage I non-seminoma within two risk-adapted SWENOTECA protocols. Acta Oncologica. 54(4). 493–499. 7 indexed citations

18.

Daneshmand, Siamak, Peter Albers, Sophie D. Fosså, et al.. (2012). Contemporary Management of Postchemotherapy Testis Cancer. European Urology. 62(5). 867–876. 77 indexed citations

19.

Fosså, Sophie D., Jan Oldenburg, & Alv A. Dahl. (2009). Short‐ and long‐term morbidity after treatment for testicular cancer. British Journal of Urology. 104(9b). 1418–1422. 30 indexed citations

20.

Fizazi, Karim, Jan Oldenburg, Ariane Dunant, et al.. (2007). Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Annals of Oncology. 19(2). 259–264. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact